pharmacokinetics of Daptomycin during CVVHF(intensive care patients continuous venovenous haemodiafiltration) in critically ill patients.
Conditions
Interventions
Trade Name: CUBICIN - 350 mg Pulver fuer ein Konz.z.Herst.e.Infusionsloesung
Product Name: CUBICIN - 350 mg Pulver fuer ein Konz.z.Herst.e.Infusionsloesung
Pharmaceutical Form: Powder and solvent for
Sponsors
Medizinische Universität Wien, Univ.Klinik f.Innere Medizin I,Abt. f. Infektionen u.Tropenmedizin
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Age >18 years - Suspected or proven bacterial infection requiring parenteral antibiotic therapy. - Continuous venovenous hemofiltration because of an acute renal failure. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - Known hypersensitivity to daptomycin. - An expected survival of less than three days. - Known pregnancy - Patients being treated with daptomycin only regimen for diagnosis of osteomyelitis, meningitis, enterococci infection or pneumonia without adequate concomitant use of other more effective antimicrobial agents (as daptomycin is not indicated for primary treatment of these types of infections)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: to investigate the pharmacokinetics of Daptomycin during CVVHF with high-flux membranes.;Secondary Objective: -;Primary end point(s): -area under the curve (AUC), -half-life (t1/2), -maximum and minimum plasma concentration (Cmax, Cmin), -total body clearance (Cltot), -hemofiltration clearance (ClHF), -sieving coefficient and the elimination fraction. | — |
Countries
Austria
Outcome results
None listed